Gensight Biologics SA - Asset Resilience Ratio

Latest as of June 2022: 59.58%

Gensight Biologics SA (SIGHT) has an Asset Resilience Ratio of 59.58% as of June 2022. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See SIGHT working capital efficiency to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

€24.15 Million

≈ $28.23 Million USD Cash + Short-term Investments

Total Assets

€40.52 Million

≈ $47.38 Million USD All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2014–2021)

This chart shows how Gensight Biologics SA's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see balance sheet size of Gensight Biologics SA.

Liquid Assets Composition Over Time

This chart breaks down Gensight Biologics SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read debt load of Gensight Biologics SA for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€24.15 Million	59.58%
Short-term Investments	€0.00	0%
Total Liquid Assets	€24.15 Million	59.58%

Asset Resilience Insights

Very High Liquidity: Gensight Biologics SA maintains exceptional liquid asset reserves at 59.58% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Gensight Biologics SA Industry Peers by Asset Resilience Ratio

Compare Gensight Biologics SA's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
argenx NV ADR NASDAQ:ARGX	Biotechnology	15.95%
Ligand Pharmaceuticals Incorporated NASDAQ:LGND	Biotechnology	16.06%
Genscript Biotech Corporation F:G51	Biotechnology	13.79%
Xiamen Amoytop Biotech Co Ltd SHG:688278	Biotechnology	4.69%
BB Biotech AG SW:BION	Biotechnology	92.97%
89bio Inc NASDAQ:ETNB	Biotechnology	71.60%
Pacific Shuanglin Bio pharmacy Co Ltd SHE:000403	Biotechnology	2.66%
Vor Biopharma Inc NASDAQ:VOR	Biotechnology	74.48%

Annual Asset Resilience Ratio for Gensight Biologics SA (2014–2021)

The table below shows the annual Asset Resilience Ratio data for Gensight Biologics SA.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2021-12-31	78.18%	€44.29 Million ≈ $51.78 Million	€56.65 Million ≈ $66.23 Million	-1.93pp
2020-12-31	80.11%	€37.94 Million ≈ $44.36 Million	€47.36 Million ≈ $55.37 Million	+20.85pp
2019-12-31	59.26%	€19.25 Million ≈ $22.51 Million	€32.48 Million ≈ $37.98 Million	-11.70pp
2018-12-31	70.96%	€26.24 Million ≈ $30.68 Million	€36.98 Million ≈ $43.23 Million	-18.17pp
2017-12-31	89.13%	€55.45 Million ≈ $64.82 Million	€62.21 Million ≈ $72.73 Million	-2.01pp
2016-12-31	91.14%	€53.98 Million ≈ $63.11 Million	€59.23 Million ≈ $69.25 Million	+81.68pp
2014-12-31	9.46%	€1.40 Million ≈ $1.64 Million	€14.82 Million ≈ $17.32 Million	--

pp = percentage points

About Gensight Biologics SA

PA:SIGHT France Biotechnology

Market Cap

$29.77 Million

€25.46 Million EUR

Market Cap Rank

#24336 Global

#391 in France

Share Price

€0.11

Change (1 day)

-0.55%

52-Week Range

€0.08 - €0.17

All Time High

€9.58